

Clot Prevention Now a Whole Lot Easier?


The role of direct Factor Xa inhibition after elective hip and knee replacement surgery

Chaired by Wolfgang Klauer and Lars Borris

Thursday 4 June 2009, 12:15–13:45

Room K, Austria Center Vienna, Vienna, Austria

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the 10th Congress of the European Federation of National Associations of Orthopaedics and Traumatology
Vienna, Austria
3–6 June 2009



Chairmen's Welcome

Dear Colleagues,

The importance of thromboprophylaxis in effectively reducing the incidence of venous thromboembolism (VTE) after major orthopaedic surgery has been firmly established.

We are delighted to host this Satellite Symposium at the 10th Congress of the European Federation of National Associations of Orthopaedics and Traumatology held in Vienna, and invite you to attend presentations that illustrate both the benefits and challenges of anticoagulant prophylaxis and how the novel, oral, direct, once-daily Factor Xa inhibitor rivaroxaban has the potential to simplify thromboprophylaxis in adult patients after elective hip and knee replacement surgery, while also providing effective reduction of symptomatic VTE.

Dr Michael Rud Lassen will open the Symposium by reviewing the consequences and costs of VTE after major orthopaedic surgery and highlight the relevance of hard endpoints, including symptomatic VTE, in clinical trials of anticoagulants. Mr John Skinner will then examine how accurately clinical trial data reflects clinical practice, with a comparison of findings from registries.

Dr Alexander GG Turpie will review the topline clinical trial data and discuss the impact of new oral anticoagulants. Finally, Dr Lars Borris will present patient case histories in an interactive session to highlight key issues and challenges that arise in clinical practice.

We hope that you will be able to join us for what promises to be an interesting and informative session.

Kind regards



Wolfgang Klauser



Lars Borris

Clot Prevention Now a Whole Lot Easier?

The role of direct Factor Xa inhibition after elective hip and knee replacement surgery


Chaired by Wolfgang Klauser and Lars Borris

Thursday 4 June 2009, 12:15–13:45

Austria Center Vienna, Vienna, Austria

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the EFORT Annual Congress 2009, 3–6 June 2009

- | | |
|-------|---------------------------------------------------------------------------------------------------|
| 12:15 | Welcome and introduction
Wolfgang Klauser, Germany |
| 12:20 | VTE after major orthopaedic surgery: consequences and costs
Michael Rud Lassen, Denmark |
| 12:40 | Are clinical trials different from clinical practice?
John Skinner, UK |
| 13:00 | Thromboprophylaxis simplified? Impact of new oral agents
Alexander GG Turpie, Canada |
| 13:20 | New options: improved outcomes? An interactive case discussion
Lars Borris, Denmark |
| 13:40 | Summary and close
Lars Borris, Denmark |



Faculty

Chairs:

Dr Wolfgang Klauser

Endo-Klinik Hamburg
Hamburg, Germany

Dr Lars Borris

Aarhus University Hospital
Aarhus, Denmark

Speakers:

Dr Michael Rud Lassen

Nordsjællands Hospital, University of Copenhagen
Hoersholm, Denmark

Mr John Skinner

University College
London, UK

Dr Alexander GG Turpie

McMaster University and Hamilton Health Sciences
Hamilton, Ontario, Canada

Dr Lars Borris

Aarhus University Hospital
Aarhus, Denmark

Sponsored by Bayer Schering Pharma AG

The marketing authorization for this product may vary from country to country. In Austria, rivaroxaban is approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip and knee replacement surgery.



Bayer HealthCare
Bayer Schering Pharma